Related Experiment Videos
Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells
B N Cronstein1, M A Eberle, H E Gruber
1Department of Medicine, New York University Medical Center, NY 10016.
Abstract:
Although commonly used to control a variety of inflammatory diseases, the mechanism of action of a low dose of methotrexate remains a mystery. Methotrexate accumulates intracellularly where it may interfere with purine metabolism. Therefore, we determined whether a 48-hr pretreatment with methotrexate affected adenosine release from [14C]adenine-labeled human fibroblasts and umbilical vein endothelial cells. Methotrexate significantly increased adenosine release by fibroblasts from 4 +/- 1% to 31 +/- 6% of total purine released (EC50, 1 nM) and by endothelial cells from 24 +/- 4% to 42 +/- 7%. Methotrexate-enhanced adenosine release from fibroblasts was further increased to 51 +/- 4% (EC50, 6 nM) and from endothelial cells was increased to 58 +/- 5% of total purine released by exposure to stimulated (fMet-Leu-Phe at 0.1 microM) neutrophils. The effect of methotrexate on adenosine release was not due to cytotoxicity since cells treated with maximal concentrations of methotrexate took up [14C]adenine and released 14C-labeled purine (a measure of cell injury) in a manner identical to control cells. Methotrexate treatment of fibroblasts dramatically inhibited adherence to fibroblasts by both unstimulated neutrophils (IC50, 9 nM) and stimulated neutrophils (IC50, 13 nM). Methotrexate treatment inhibited neutrophil adherence by enhancing adenosine release from fibroblasts since digestion of extracellular adenosine by added adenosine deaminase completely abrogated the effect of methotrexate on neutrophil adherence without, itself, affecting adherence. One hypothesis that explains the effect of methotrexate on adenosine release is that, by inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) transformylase, methotrexate induces the accumulation of AICAR, the nucleoside precursor of which (5-aminoimidazole-4-carboxamide ribonucleoside referred to hereafter as acadesine) has previously been shown to cause adenosine release from ischemic cardiac tissue. We found that acadesine also promotes adenosine release from and inhibits neutrophil adherence to connective tissue cells. The observation that the antiinflammatory actions of methotrexate are due to the capacity of methotrexate to induce adenosine release may form the basis for the development of an additional class of antiinflammatory drugs.
Insights
Low-dose methotrexate increases adenosine release from cells, reducing neutrophil adherence. This mechanism, involving AICAR accumulation, may explain its anti-inflammatory effects and guide new drug development.
Area of Science:
- Pharmacology
- Immunology
- Cell Biology
Background:
- Low-dose methotrexate is widely used for inflammatory diseases, but its mechanism of action is not fully understood.
- Methotrexate accumulates intracellularly and may impact purine metabolism.
Purpose of the Study:
- To investigate whether methotrexate pretreatment affects adenosine release from human fibroblasts and umbilical vein endothelial cells.
- To determine if methotrexate-induced adenosine release influences neutrophil adherence to these cells.
Main Methods:
- Human fibroblasts and endothelial cells were pretreated with methotrexate.
- Adenosine release was measured using [14C]adenine labeling.
- Neutrophil adherence to treated cells was assessed, and the role of adenosine was confirmed using adenosine deaminase.
Main Results:
- Methotrexate significantly increased adenosine release from both fibroblasts and endothelial cells in a dose-dependent manner.
- Methotrexate treatment markedly inhibited neutrophil adherence to fibroblasts, an effect reversed by adenosine deaminase.
- The proposed mechanism involves methotrexate-induced accumulation of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), leading to acadesine production and subsequent adenosine release.
Conclusions:
- Methotrexate's anti-inflammatory effects may stem from its ability to induce adenosine release, which inhibits neutrophil adherence.
- This mechanism provides a basis for developing novel anti-inflammatory drugs targeting adenosine pathways.